Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fabry disease.

Literature DB >> 12860841

Fabry disease.

S F Nagueh.

Abstract

Entities: Disease

Mesh：

Year: 2003 PMID： 12860841 PMCID： PMC1767779 DOI： 10.1136/heart.89.8.819

Source DB: PubMed Journal: Heart ISSN： 1355-6037 Impact factor: 5.994

× No keyword cloud information.

14 in total

1. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy?

Authors: S R Ommen; R A Nishimura; W D Edwards
Journal: Heart Date: 2003-08 Impact factor: 5.994

2. Fabry disease: an unusual cause of severe coronary disease in a young man.

Authors: E A Fisher; R J Desnick; R E Gordon; C M Eng; R Griepp; M E Goldman
Journal: Ann Intern Med Date: 1992-08-01 Impact factor: 25.391

3. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors: C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal: N Engl J Med Date: 2001-07-05 Impact factor: 91.245

4. Sisters with atypical Fabry's disease with complete atrioventricular block.

Authors: Y Doi; G Toda; K Yano
Journal: Heart Date: 2003-01 Impact factor: 5.994

5. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.

Authors: S C Jung; I P Han; A Limaye; R Xu; M P Gelderman; P Zerfas; K Tirumalai; G J Murray; M J During; R O Brady; P Qasba
Journal: Proc Natl Acad Sci U S A Date: 2001-02-27 Impact factor: 11.205

6. Early detection of Fabry cardiomyopathy by tissue Doppler imaging.

Authors: Maurizio Pieroni; Cristina Chimenti; Roberta Ricci; Patrizio Sale; Matteo Antonio Russo; Andrea Frustaci
Journal: Circulation Date: 2003-03-31 Impact factor: 29.690

7. An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

Authors: S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba
Journal: N Engl J Med Date: 1995-08-03 Impact factor: 91.245

8. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies.

Authors: R J Desnick; L C Blieden; H L Sharp; P J Hofschire; J H Moller
Journal: Circulation Date: 1976-11 Impact factor: 29.690

9. Electrocardiographic and vectorcardiographic abnormalities in Fabry's disease.

Authors: J Mehta; N Tuna; J H Moller; R J Desnick
Journal: Am Heart J Date: 1977-06 Impact factor: 4.749

10. The M-mode echocardiogram in Fabry's disease.

Authors: J L Bass; S Shrivastava; G A Grabowski; R J Desnick; J H Moller
Journal: Am Heart J Date: 1980-12 Impact factor: 4.749

13 in total

1. Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy.

Authors: G Messalli; M Imbriaco; G Avitabile; R Russo; D Iodice; L Spinelli; S Dellegrottaglie; F Cademartiri; M Salvatore; A Pisani
Journal: Radiol Med Date: 2011-07-09 Impact factor: 3.469

2. Early cardiac changes in children with anderson-fabry disease.

Authors: Stepan Havranek; Ales Linhart; Zuzana Urbanova; Uma Ramaswami
Journal: JIMD Rep Date: 2013-04-02

3. Successful management of enzyme replacement therapy in related fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme(®)) to agalsidase alfa (replagal (®)).

Authors: Kazuya Tsuboi; Hiroshi Yamamoto; Fuji Somura; Hiromi Goto
Journal: JIMD Rep Date: 2014-04-10

4. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.

Authors: Akemi Tanaka; Taisuke Takeda; Takao Hoshina; Kazuyoshi Fukai; Tsunekazu Yamano
Journal: J Inherit Metab Dis Date: 2010-06-22 Impact factor: 4.982

5. Improvement in the sensitivity of newborn screening for Fabry disease among females through the use of a high-throughput and cost-effective method, DNA mass spectrometry.

Authors: Yung-Hsiu Lu; Po-Hsun Huang; Li-Yun Wang; Ting-Rong Hsu; Hsing-Yuan Li; Pi-Chang Lee; Yu-Ping Hsieh; Sheng-Che Hung; Yu-Chen Wang; Sheng-Kai Chang; Ya-Ting Lee; Ping-Hsun Ho; Hui-Chen Ho; Dau-Ming Niu
Journal: J Hum Genet Date: 2017-11-15 Impact factor: 3.172

9. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).

Authors: Kazuya Tsuboi; Hiroshi Yamamoto
Journal: Genet Med Date: 2012-04-12 Impact factor: 8.822

10. Descriptive epidemiology of Fabry disease among beneficiaries of the Specified Disease Treatment Research Program in Japan.

Authors: Kazuya Tsuboi; Sadao Suzuki; Masaki Nagai
Journal: J Epidemiol Date: 2012-06-09 Impact factor: 3.211